Tech Company Financing Transactions

Talaris Therapeutics Funding Round

Talaris Therapeutics closed a $100 million Series A financing round on 4/19/2019. Investors included Blackstone, Longitude Capital Management and Qiming Ventures.

Transaction Overview

Company Name
Talaris Therapeutics
Announced On
4/19/2019
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors

Blackstone (Lead Investor) (Nicholas Galakatos)

Longitude Capital Management (Sandip Agarwala)

Qiming Ventures (Mark McDade)

Proceeds Purpose
The Series A funding will be used to advance the company's proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development in multiple immune-related indications.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
201 East Jefferson St. 110B
Louisville, KY 40202
USA
Phone
(502) 569-1059
Website
www.talaristx.com
Email Address
[email protected]
Overview
Talaris is developing a single-dose cell therapy that seeks to free organ transplant recipients of the burdens and toxicities of lifelong immunosuppression, without rejecting their transplanted organ.
Profile
Talaris Therapeutics LinkedIn Company Profile
Social Media
Talaris Therapeutics Company Twitter Account
Company News
Talaris Therapeutics News
Facebook
Talaris Therapeutics on Facebook
YouTube
Talaris Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Scott Requadt
  Scott Requadt LinkedIn Profile  Scott Requadt Twitter Account  Scott Requadt News  Scott Requadt on Facebook
Chief Financial Officer
Gregg Beloff
  Gregg Beloff LinkedIn Profile  Gregg Beloff Twitter Account  Gregg Beloff News  Gregg Beloff on Facebook
Chief Marketing Officer
Nancy Krieger
  Nancy Krieger LinkedIn Profile  Nancy Krieger Twitter Account  Nancy Krieger News  Nancy Krieger on Facebook
Chief Scientific Officer
Suzanne Ildstad
  Suzanne Ildstad LinkedIn Profile  Suzanne Ildstad Twitter Account  Suzanne Ildstad News  Suzanne Ildstad on Facebook
Vice President
Mary West
  Mary West LinkedIn Profile  Mary West Twitter Account  Mary West News  Mary West on Facebook
VP - Finance
Keith McCormick
  Keith McCormick LinkedIn Profile  Keith McCormick Twitter Account  Keith McCormick News  Keith McCormick on Facebook
VP - Human Resources
Roderick Purdy
  Roderick Purdy LinkedIn Profile  Roderick Purdy Twitter Account  Roderick Purdy News  Roderick Purdy on Facebook
VP - Manufacturing
Devin Blass
  Devin Blass LinkedIn Profile  Devin Blass Twitter Account  Devin Blass News  Devin Blass on Facebook
VP - Operations
Suzanne Tollerud
  Suzanne Tollerud LinkedIn Profile  Suzanne Tollerud Twitter Account  Suzanne Tollerud News  Suzanne Tollerud on Facebook
VP - Product Management
Eric Gornstein
  Eric Gornstein LinkedIn Profile  Eric Gornstein Twitter Account  Eric Gornstein News  Eric Gornstein on Facebook
VP - Regulatory Affairs
Andrew Beavis
  Andrew Beavis LinkedIn Profile  Andrew Beavis Twitter Account  Andrew Beavis News  Andrew Beavis on Facebook
VP - Regulatory Affairs
Sue Graumlich
  Sue Graumlich LinkedIn Profile  Sue Graumlich Twitter Account  Sue Graumlich News  Sue Graumlich on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/19/2019: Gen.G venture capital transaction
Next: 4/19/2019: Emergency Reporting venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.